Just keep hiring consultants with very little to none-at-all ability to work on the new drugs, but keep the same sales force. The two together are pretty much a perfect recipe for a disaster. They are damaging the sales of OFIRMEV and why they are doing this is beyond me – makes no business sense at all and it just tells you about their ability to manage a high stakes business…
1 reply
And yes, pharmacy will catch on to this in no time, they are not stupid. Surgeons could give a f--- about Topical Thrombin – that’s a fact, ask any of them. With this in mind, good luck to us competing with JnJ! What a bad acquisition really…
Do they even have a clue how long it takes to add a product through materials?